Healthcare
Australia’s second-largest member-based insurer is expanding its portfolio to invest in health tech startups. And it’s confident it can succeed where other corporate VCs failed.
CEO Sam Hupert argues the company continues to deliver a strong pipeline of contracts and is well placed to excel in the AI age.
For all our talk of productivity and sovereign capability, we’re overlooking one of the smartest investments we can make.
Mayne is considering a split of its operations to help shareholders recover from unrealised losses after Cosette’s $600 million takeover deal collapsed in December.
After a transformative run of regulatory wins and commercial deals, the company has secured the backing of major investors in the first big equity raise of the year led by Bell Potter.
The $2.3b market darling is expected to raise $150m after an extraordinary 5-month share price surge, but investors are split on whether the dream run can continue.
On the cusp of becoming Australia's next unicorn, Euc has parted ways with senior staff and paused a product expansion to focus on its core business. Investors say that's a good thing.
Public health may never fund prevention properly. But technology and consumer curiosity could drive a new era of proactive, personalised healthcare.
The unicorn hopeful has put its men’s longevity play on the backburner as it pushes to expand women’s weight loss brand Juniper’s product offering in the UK.
